Free Trial

Chapin Davis Inc. Buys New Shares in LivaNova PLC (NASDAQ:LIVN)

LivaNova logo with Medical background

Chapin Davis Inc. purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 17,000 shares of the company's stock, valued at approximately $668,000.

Several other institutional investors also recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its holdings in LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after purchasing an additional 1,424 shares in the last quarter. Rhumbline Advisers grew its holdings in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of LivaNova during the fourth quarter valued at about $2,772,000. Envestnet Asset Management Inc. grew its stake in shares of LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after acquiring an additional 5,850 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of LivaNova by 147.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock valued at $4,582,000 after acquiring an additional 58,911 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded down $0.07 during midday trading on Thursday, hitting $45.80. 308,949 shares of the company's stock were exchanged, compared to its average volume of 637,942. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.58 and a quick ratio of 1.37. The stock's 50 day moving average price is $42.47 and its 200-day moving average price is $43.55. The firm has a market cap of $2.50 billion, a P/E ratio of -11.20 and a beta of 0.90. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. The Goldman Sachs Group decreased their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Finally, Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus target price of $59.29.

Check Out Our Latest Research Report on LIVN

About LivaNova

(Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Should You Invest $1,000 in LivaNova Right Now?

Before you consider LivaNova, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.

While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines